Angiogenesis and vascular targeting: relevance for hyperthermia

Area of Science:

• Oncology
• Vascular Biology
• Radiation Oncology

Background:

• Tumor growth relies on angiogenesis, forming a functional blood supply.
• Vascular targeting agents (VTAs) aim to disrupt tumor vasculature, including angiogenesis inhibiting agents (AIAs) and vascular disrupting agents (VDAs).
• Tumor vasculature significantly impacts hyperthermia treatment efficacy.

Purpose of the Study:

• To explore the synergistic potential of combining vascular targeting agents (VTAs) with hyperthermia and radiation therapy for solid tumors.
• To evaluate the efficacy and therapeutic window of combined VTA-heat and VTA-heat-radiation treatment strategies.

Main Methods:

• Pre-clinical studies investigating the combination of angiogenesis inhibiting agents (AIAs) or vascular disrupting agents (VDAs) with hyperthermia.
• Assessment of vascular disrupting agents (VDAs) in combination with hyperthermia for enhancing thermoradiosensitisation.
• Evaluation of normal tissue response to combined radiation, VDAs, and heat treatments.

Main Results:

• Pre-clinical studies demonstrate improved tumor response when combining AIAs or VDAs with heat.
• Vascular disrupting agents (VDAs) enhance thermoradiosensitisation, particularly at mild hyperthermia temperatures.
• Combined radiation, VDAs, and heat show a therapeutic benefit with less normal tissue toxicity compared to tumors.

Conclusions:

• Combining vascular targeting agents (VTAs), especially VDAs, with hyperthermia presents a logical and effective therapeutic strategy.
• The combination of VDAs with heat and radiation demonstrates a significant therapeutic advantage, with manageable normal tissue effects.
• Pre-clinical evidence strongly supports the translation of these combined treatment modalities into clinical trials for solid tumors.